Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Geneplus-Beijing Co. Ltd.
With
Chinese Academy of Medical Sciences
Age
30–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
With confirmed pathological diagnosis and molecular subtyping results
Ability to provide a written informed consent
You may not be if
Patients with a history of or currently suffering from other malignancies
Pregnant or planning to become pregnant female patients
Patients who have received cancer treatment, including surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, before blood draw
Patients with a history of blood transfusion within the past month
Patients with a known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation
Patients with persistent fever or undergoing anti-inflammatory treatment within 14 days before blood draw
Any other conditions that the researcher deems may make the patient unsuitable for inclusion in the study or may interfere with the completion of the study
Patients in poor physical condition who are not suitable for blood draw
Patients who cannot provide informed consent or refuse blood draw
History of malignancies
Current malignancies or precancerous lesions
Clareo Health | Application of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer
